Two-Year Randomized Controlled Prospective Trial Converting Treatment of Stable Renal Transplant Recipients With Cutaneous Invasive Squamous Cell Carcinomas to Sirolimus

Randomized Controlled Trial of Sirolimus for Renal Transplant Recipients at High Risk for Nonmelanoma Skin Cancer

(2012) S. B. Campbell et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Sirolimus and Secondary Skin-Cancer Prevention in Kidney Transplantation

(2012) Sylvie Euvrard et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Case-Control Study of Betapapillomavirus Infection and Cutaneous Squamous Cell Carcinoma in Organ Transplant Recipients

(2011) C. M. Proby et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial

(2011) Josefina Alberú et al.   TRANSPLANTATION

Switch to a Sirolimus-Based Immunosuppression in Long-Term Renal Transplant Recipients: Reduced Rate of (Pre-)Malignancies and Nonmelanoma Skin Cancer in a Prospective, Randomized, Assessor-Blinded, Controlled Clinical Trial

(2010) R. Salgo et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Incidence of cancer in kidney-transplant recipients: A long-term cohort study in a single center

(2010) Hermina C. Wisgerhof et al.   Cancer Epidemiology

Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial

(2010) Matthew R. Weir et al.   KIDNEY INTERNATIONAL

Opposing roles for calcineurin and ATF3 in squamous skin cancer

(2010) Xunwei Wu et al.   NATURE

Subsequent Squamous- and Basal-Cell Carcinomas in Kidney-Transplant Recipients After the First Skin Cancer: Cumulative Incidence and Risk Factors

(2010) Hermina C. Wisgerhof et al.   TRANSPLANTATION

Predicting Risk of Nonmelanoma Skin Cancer and Premalignant Skin Lesions in Renal Transplant Recipients

(2009) Helen R. Urwin et al.   TRANSPLANTATION

Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial

(2009) Francesco P. Schena et al.   TRANSPLANTATION

Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin

(2008) B. I. Rini   CLINICAL CANCER RESEARCH